Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
April 22, 2022 17:15 ET
|
Iovance Biotherapeutics, Inc.
SAN CARLOS, Calif., April 22, 2022 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today...
Iovance Biotherapeutics Announces Regulatory and Clinical Updates for Lifileucel in Melanoma
April 05, 2022 16:05 ET
|
Iovance Biotherapeutics, Inc.
Positive FDA Feedback on Potency Assay Matrix to Support BLA Submission Further Defines Frontline Melanoma Strategy for Lifileucel in Combination with Pembrolizumab SAN CARLOS, Calif., April 05,...
Iovance Biotherapeutics to Present at Upcoming Conferences
March 16, 2022 07:01 ET
|
Iovance Biotherapeutics, Inc.
SAN CARLOS, Calif., March 16, 2022 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today...
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
March 15, 2022 17:15 ET
|
Iovance Biotherapeutics, Inc.
SAN CARLOS, Calif., March 15, 2022 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today...
Iovance Biotherapeutics’ Investigational New Drug Application (IND) Allowed to Proceed for TALEN®-Edited Tumor Infiltrating Lymphocyte (TIL) in Unresectable or Metastatic Melanoma and Stage III or IV Non-Small Cell Lung Cancer (NSCLC)
March 15, 2022 16:01 ET
|
Iovance Biotherapeutics, Inc.
Clinical Study Expected to Begin in 2022 to Investigate the Safety and Efficacy of IOV-4001Â to Deliver TIL and PD-1 Inhibition within a Single Cancer Therapy First Genetically Modified Iovance TIL...
Iovance Biotherapeutics to Present at American Association for Cancer Research (AACR) 2022 Annual Meeting
March 08, 2022 16:31 ET
|
Iovance Biotherapeutics, Inc.
SAN CARLOS, Calif., March 08, 2022 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today...
Iovance Biotherapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Corporate Updates
February 24, 2022 16:01 ET
|
Iovance Biotherapeutics, Inc.
SAN CARLOS, Calif., Feb. 24, 2022 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies (tumor...
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
February 18, 2022 17:15 ET
|
Iovance Biotherapeutics, Inc.
SAN CARLOS, Calif., Feb. 18, 2022 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today...
Iovance Biotherapeutics to Host Fourth Quarter and Full Year Financial Results Conference Call and Webcast on Thursday, February 24, 2022
February 11, 2022 16:01 ET
|
Iovance Biotherapeutics, Inc.
SAN CARLOS, Calif., Feb. 11, 2022 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, will...
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
January 21, 2022 17:15 ET
|
Iovance Biotherapeutics, Inc.
SAN CARLOS, Calif., Jan. 21, 2022 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today...